NCT03552068View on ClinicalTrials.gov

Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

July 15, 2021

Study Completion Date

December 3, 2021

Conditions
Parkinson's DiseaseMpulse Control Disorders
Interventions
DRUG

placebo

"Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks.~Medication: placebo twice a day (in the morning and evening)."

DRUG

Clonidine

Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 μg of clonidine twice a day (in the morning and evening).

Trial Locations (1)

Unknown

Hospices Civils de Lyon, Bron

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03552068 - Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease: | Biotech Hunter | Biotech Hunter